Pfizer’s associate general counsel, Justin McCarthy, has sent a letter to India’s ambassador to the US, Subrahmanyam Jaishankar, urging the Indian government to “shift from using destructive IP policy as an access strategy,” according to reports.
Novartis and GSK have agreed to create a consumer healthcare business in a joint venture that involves the exchange of assets worth billions of dollars.
Depomed, a California-based pharmaceutical company, has settled litigation with two of three companies that sought to launch generic versions of its Gralise (gabapentin) product before patents covering it expire.
US-based The Medicines Co has sued Aurobindo Pharma after claims the Indian pharmaceutical company infringed two patents related to its heart drug Angiomax (bivalirudin).
A group of generic drug manufacturers has asked the US Supreme Court to allow a ruling that grants them permission to market a version of Teva’s multiple sclerosis drug Copaxone (glatiramer acetate).
The UK High Court has invalidated two patents covering Roche’s breast cancer drug Herceptin (trastuzumab) after a challenge by generic drug maker Hospira.
Law firm Mintz Levin Cohn Ferris Glovsky and Popeo PC has added three partners to its IP team.
US law firm O’Melveny & Myers LLP has hired Lisa Barons Pensabene, Marc Pensabene, and Filko Prugo at its New York office.
Dublin-based Mallinckrodt Pharmaceuticals has announced it will buy US biopharmaceutical company Questcor Pharmaceuticals for $5.6 billion.
OxyContin (oxycodone hydrochloride) maker Purdue Pharma has filed suit against Teva to stop the generic drug maker trying to litigate claims to a patent for which it had filed a Paragraph III certification.